Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants

Takeda spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants jwaldron Mon, 07/08/2024 - 08:42